AN EVALUATION OF THE BUDGET IMPACT OF THE NEW 20% SUBCUTANEOUS IMMUNOGLOBULIN (IG20GLY) FOR THE MANAGEMENT OF PRIMARY IMMUNODEFICIENCY DISEASES IN SWITZERLAND
Author(s)
Pollock RF1, Meckley LM2
1Ossian Health Economics and Communications GmbH, Basel, Switzerland, 2Shire, Plc, Cambridge, MA, USA
OBJECTIVES: Patients with primary immunodeficiency diseases (PID) are frequently treated with immunoglobulin (Ig) replacement therapy, either intravenously (IVIG) or subcutaneously (SCIG), to prevent infections. The objective of this analysis was to evaluate the budget impact of the introduction of CUVITRU® [Immune Globulin Subcutaneous (Human)] 20% solution (Ig20Gly; Shire) for the treatment of children and adults with PID in Switzerland. METHODS: A budget impact model assessing Ig for patients with PID was developed in Microsoft Excel from the perspective of a Swiss health insurance provider. The model focused on the administration cost of Ig, with all types of Ig, in all treatment settings, and did not include infections or adverse events based on the assumption that all Ig formulations have similar efficacy. Literature-based sources were used to estimate the prevalence of PID, proportion of patients treated with Ig, and treatment site of care. Market research and assumptions were used to estimate Ig treatment patterns and changes in treatment patterns over time. Unit costs were based on a recent cost-minimization analysis of SCIG in Lausanne, and drug costs came from the Spezialitätenliste Future costs were not discounted. RESULTS: Costs of Ig treatment for PID in Switzerland over 3 years were estimated to be: CHF 11.16m, with drug costs comprising CHF 9.28m, and ancillary costs comprising CHF 1.87m (healthcare professional time and other administration costs, [e.g., pumps and needle sets]). The analysis found that using Ig20Gly in place of other SCIG formulations would be cost neutral, while using Ig20Gly in place of IVIG would result in savings of 4.0%. CONCLUSIONS: Ig20Gly would be cost neutral relative to existing SCIG products and would result in cost savings relative to IVIG in patients with PID in Switzerland, even with modest uptake.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSY27
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Rare and Orphan Diseases